<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222545</url>
  </required_header>
  <id_info>
    <org_study_id>OMS721-TMA-001</org_study_id>
    <secondary_id>2014-001032-11</secondary_id>
    <nct_id>NCT02222545</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies</brief_title>
  <official_title>A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeros Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeros Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and clinical activity of
      OMS721 in subjects with thrombotic microangiopathies (TMA), which include atypical hemolytic
      uremic syndrome (aHUS), thrombotic thrombocytopenia (TTP), and hematopoietic stem cell
      transplant -associated TMA (HSCT-associated TMA). The study will also evaluate clinical
      activity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-drug antibody response
      (ADA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, uncontrolled, three-stage, dose-escalation cohort study in subjects with
      three forms of TMA: atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenia
      (TTP), and hematopoietic stem cell transplant -associated TMA (HSCT-associated TMA). In the
      first stage, OMS721 will be administered to escalating dose cohorts of three subjects per
      cohort to identify the optimal dosing regimen. In the second stage, the dose selected in the
      first stage will be administered to expanded cohorts of 40 subjects per cohort with distinct
      etiologies (aHUS alone in one cohort and TTP or HSCT-TMA in the other cohort). Subjects
      completing the second stage may be eligible for continued treatment in the third stage if the
      investigator believes the subject is at risk for relapse of TMA, the subject tolerated OMS721
      treatment, and the subject has no conditions that increase the risk of OMS721 treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety and tolerability of multiple-dose administration of OMS721 in subjects with TMA</measure>
    <time_frame>4 to 24 weeks</time_frame>
    <description>Incidence of Adverse Events, vital signs, ECG, and clinical laboratory tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the clinical activity of multiple-dose administration of OMS721 in subjects with TMA</measure>
    <time_frame>4 to 24 weeks</time_frame>
    <description>Clinical activity as assessed by platelet count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of multiple-dose administration of OMS721 in subjects with TMA</measure>
    <time_frame>Pre-dose and up to 204 days post-dose</time_frame>
    <description>PK parameters including maximum concentration, time to maximum concentration, elimination half-life, area under time-concentration curve, clearance, and volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of multiple-dose administration of OMS721 in subjects with TMA</measure>
    <time_frame>Pre-dose and up to 204 days post-dose</time_frame>
    <description>PD measure of inhibition of ex vivo lectin pathway activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of multiple-dose administration of OMS721 in subjects with TMA</measure>
    <time_frame>Pre-dose and up to 204 days post-dose</time_frame>
    <description>Presence of ADA response</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">89</enrollment>
  <condition>Thrombotic Microangiopathies</condition>
  <arm_group>
    <arm_group_label>OMS721 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of OMS721 at a low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMS721 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of OMS721 at a medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMS721 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of OMS721 at a high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OMS721</intervention_name>
    <arm_group_label>OMS721 low dose</arm_group_label>
    <arm_group_label>OMS721 medium dose</arm_group_label>
    <arm_group_label>OMS721 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Are at least age 18 at screening (Visit 1)

          2. Have a diagnosis of primary aHUS, persistent HSCT-associated TMA or TTP

          3. No clinically apparent alternative explanation for thrombocytopenia and anemia

        Exclusion Criteria:

          1. Had eculizumab therapy within three months prior to screening

          2. Have STEC-HUS

          3. Have a positive direct Coombs test

          4. Have an active systemic bacterial or fungal infection requiring antimicrobial therapy
             (prophylactic antimicrobial therapy administered as standard of care is allowed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Soyoung Han</last_name>
    <phone>206-676-0819</phone>
    <email>shan@omeros.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danielle Barnhart</last_name>
    <phone>206-676-5051</phone>
    <email>dbarnhart@omeros.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Pok Fu Lam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Pathum Thani</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Pathumwan</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Songkhla</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMA, aHUS, HSCT-associated TMA, TTP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Thrombotic Microangiopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

